shares of oric pharmaceuticals inc jumped nearly 60 to 479 in premarket trading thursday after the company agreed to sell 25 million in shares to pfizer inc the clinicalstage oncology company said wednesday evening that pfizer has agreed to buy nearly 54 million shares of orics common stock for 465 apiece the investment is part of a clinical development collaboration between the two companies on a phase 2 study examining orics oric533 treatment for multiple myeloma the companies said the companies said the collaboration would potentially advance the treatment into a combination study with pfizers elranatamab an investigational treatment for multiple myeloma